COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook
Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios. Stock Performance Overview (Nov 2025) COMPASS Pathways’ stock has experienced considerable volatility in 2025, mirroring the company’s clinical trial news cycle. As of November 4, 2025, CMPS trades in the mid-$5 range (around $5.95–$6.00), roughly flat versus a week prior intellectia.ai. This price is well above its summertime lows, but slightly off the highs reached in October. Recent Trading Range: In mid-October 2025, CMPS rallied to $6.76 per share, marking a new 52-week high
